Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To evaluate the safety and tolerability of orally administered OPC-67683 when
administered two times daily (BID) to MDR TB patients refractory to treatment with an
optimized background regimen of anti-TB medications (OBR).
- To evaluate the pharmacokinetics (PK) of OPC-67683 and metabolites.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.